79069-51-5

Usage

InChI:InChI=1/C10H19NO3/c1-7(2)8(6-12)11-9(13)14-10(3,4)5/h6-8H,1-5H3,(H,11,13)/t8-/m1/s1

Upstream product

• 58561-04-9 N-tert-butoxycarbonyl-L-valine methyl ester 
• 79069-14-0 (S)-2-<(tert-butoxycarbonyl)amino>-3-methylbutan-1-ol 
• 133010-02-3 1,1-dimethylethyl S-N-(1-fluorocarbonyl-2-methylpropyl)carbamate 
• 13734-41-3 t-Boc-L-valine 
• 534568-55-3 Boc-Val-SEt 
• 3392-12-9 Boc-Val-ONSu 
• 72-18-4 L-valine 
• 4070-48-8 L-Valine methyl ester 
• 2026-48-4 (S)-valinol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 98807-40-0 Boc-Val-O-COOEt 
• 54430-66-9 [(1S)-1-(imidazole-1-carbonyl)-2-methylpropyl]-carbamic acid tert-butyl ester 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 118517-07-0 C₁₄H₂₅NO₆ 

Downstream Products

• 143327-78-0 tert-butyl [(1S)-1-isopropylprop-2-yn-1-yl]carbamate 
• 115378-34-2 (3S)-3-(tert-butoxycarbonylamino)-4-methyl-1-pentene 
• 104739-62-0 N-(2-Boc-amino-3-methylbutyliden)-L-phenylalanin-N-oxid-methylester 
• 138802-19-4 [(1S,2R,3R)-2-Hydroxy-1-isopropyl-3-methyl-4-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-yl)-4-oxo-butyl]-carbamic acid tert-butyl ester 
• 140199-90-2 (S,Z)-3-(tert-butoxycarbonylamino)-2-methyl-4-hexene 
• 170080-38-3 (S,E)-3-(tert-butoxycarbonylamino)-2-methyl-4-hexene 
• 195059-41-7 (Z)-N-[(2S)-2-(tert-butoxycarbonylamino)-1-methylbutylidene] benzylamine N-oxide 
• 95501-78-3 N-Benzyloxycarbonyl-L-valyl-L-prolyl-L-valinal 
• 226413-52-1 2-((2S)-2-tert-butoxycarbonylamino-1-hydroxy-3-methylbutyl)-3-phenylcyclopropenone 2,2-dimethyl-1,3-propanediyl acetal 
• 289708-00-5 2-tert-butoxycarbonylamino-3-phenyl-propionic acid 2-tert-butoxycarbonylamino-1-(methoxycarbonylmethyl-carbamoyl)-3-methyl-butyl ester 

Relevant academic research and scientific papers

Efficient Entropy-Driven Inhibition of Dipeptidyl Peptidase III by Hydroxyethylene Transition-State Peptidomimetics

Dipeptidyl peptidase III (DPP3) is a ubiquitously expressed Zn-dependent protease, which plays an important role in regulating endogenous peptide hormones, such as enkephalins or angiotensins. In previous biophysical studies, it could be shown that substr

Asymmetric Aza-Claisen Rearrangement between Enantioenriched α-Chiral Allylamines and Allenones

An unprecedented asymmetric aza-Claisen rearrangement between enantioenriched α-chiral allylamines and allenones was found to proceed in the absence of catalysts and additives at room temperature. The rearrangement, followed by hydrolysis, provides convenient access to structurally diverse δ-chiral β-diketones in good to excellent yields with excellent retention of enantiopurity. This protocol proved powerful for the construction of an all-carbon quaternary stereocenter with high enantiopurity.

N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing (or inhibiting) cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Synthesis of Enantiomerically Pure 3-Substituted Piperazine-2-acetic Acid Esters as Intermediates for Library Production

The piperazine heterocycle is broadly exploited in FDA-approved drugs and biologically active compounds, but its chemical diversity is usually limited to ring nitrogen substitutions, leaving the four carbon atoms underutilized. Using an efficient six-step synthesis, chiral amino acids were transformed into 3-substituted piperazine-2-acetic acid esters as diastereomeric mixtures whose cis and trans products (dr 0.56 a? 2.2:1, respectively) could be chromatographically separated. From five amino acids (both antipodes) was obtained a complete matrix of 20 monoprotected chiral 2,3-disubstituted piperazines, each as a single absolute stereoisomer, all but one in multigram quantities. In keeping with our overall purpose of constructing more Csp3-enriched compound libraries for drug discovery, these diverse and versatile piperazines can be functionalized on either nitrogen atom, allowing them to be used as scaffolds for parallel library synthesis and as intermediates for the production of novel piperazine compounds.

NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10 and R11 are as described herein, compositions including the compounds and methods of using the compounds.

METHOD FOR PRODUCING ALDEHYDE

PROBLEM TO BE SOLVED: To provide a new method for producing aldehyde capable of evading reduction under low temperature conditions and having higher selectivity. SOLUTION: Provided is a method for producing aldehyde where activated ester is prepared from carboxylic acid such as saturated fatty acid, unsaturated fatty acid, hydroxy acid, aromatic carboxylic acid and amino acid and an activation ester agent such as halogenated carbonic acid aryl, a carbodiimide-based condensation agent, an imidazole-based condensation agent and a triazine-based condensation agent, and the activated ester is reduced, and being a method for producing aldehyde in which an environmental load is reduce, and having high yield and high selectivity. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS

The invention provides novel compounds having the general formula (I) wherein wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10, R11, R12 and R23 are as described herein, compositions including the compounds and methods of using the compounds.

ALPHA-OXOACYL AMINO-CAPROLACTAM DERIVATIVE

The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in combination with another drug. The present invention relates to: an α-oxoacyl aminocaprolactam derivative that is represented by formula (I) (in the formula, X is —O— or —N(R1)— and R1 represents an alkoxycarbonyl group having 1-10 carbon atoms); and a bone resorption inhibitor containing the α-oxoacyl aminocaprolactam derivative.

ALPHA-OXOACYL AMINO-CAPROLACTAM BODY

The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in combination with another drug. The present invention relates to: an α-oxoacyl amino-caprolactam that is represented by formula (I) (in formula (I), X represents N or CH, Y represents O or CH2, and Z represents S or CH2); and a bone resorption inhibitor containing the α-oxoacyl amino-caprolactam.

Chemo- and Diastereoselective N-Heterocyclic Carbene-Catalyzed Cross-Benzoin Reactions Using N-Boc-α-amino Aldehydes

N-Boc-α-amino aldehydes are shown to be excellent partners in cross-benzoin reactions with aliphatic or heteroaromatic aldehydes. The chemoselectivity of the reaction and the facial selectivity on the amino aldehyde allow cross-benzoin products to be obtained in good yields and good diastereomeric ratios. The developed method is utilized as the key step in a concise total synthesis of d-arabino-phytosphingosine.